Last reviewed · How we verify
Cathflo Activase
At a glance
| Generic name | Cathflo Activase |
|---|---|
| Sponsor | Memorial Healthcare System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion (EARLY_PHASE1)
- Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis (PHASE2)
- Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis (PHASE4)
- EXtending the Time Window for Thrombolysis in Posterior Circulation Stroke Without Early CT Signs (PHASE3)
- Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE (PHASE4)
- Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol (NA)
- Viscoelastic Testing Guided Tissue Plasminogen Activator Treatment in Acute Respiratory Failure (PHASE2)
- TPA in Acute Stroke With COVID Verus Non-COVID-19 Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cathflo Activase CI brief — competitive landscape report
- Cathflo Activase updates RSS · CI watch RSS
- Memorial Healthcare System portfolio CI